Hcw Biologics Stock Probability Of Bankruptcy
| HCWB Stock | USD 0.61 0.16 20.78% |
HCW | Probability Of Bankruptcy |
HCW Biologics Company chance of distress Analysis
HCW Biologics' Probability Of Bankruptcy is a relative measure of the likelihood of financial distress. For stocks, the Probability Of Bankruptcy is the normalized value of Z-Score. For funds and ETFs, it is derived from a multi-factor model developed by Macroaxis. The score is used to predict the probability of a firm or a fund experiencing financial distress within the next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100, indicating the firm's actual probability it will be financially distressed in the next 2 fiscal years.
More About Probability Of Bankruptcy | All Equity Analysis
Probability Of Bankruptcy | = | Normalized | | Z-Score |
Current HCW Biologics Probability Of Bankruptcy | Over 76% |
Most of HCW Biologics' fundamental indicators, such as Probability Of Bankruptcy, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, HCW Biologics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Our calculation of HCW Biologics probability of bankruptcy is based on Altman Z-Score and Piotroski F-Score, but not limited to these measures. To be applied to a broader range of industries and markets, we use several other techniques to enhance the accuracy of predicting HCW Biologics odds of financial distress. These include financial statement analysis, different types of price predictions, earning estimates, analysis consensus, and basic intrinsic valuation. Please use the options below to get a better understanding of different measures that drive the calculation of HCW Biologics financial health.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of HCW Biologics. If investors know HCW will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about HCW Biologics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.05) | Revenue Per Share 0.107 | Quarterly Revenue Growth (0.01) | Return On Assets (0.70) | Return On Equity (3.44) |
The market value of HCW Biologics is measured differently than its book value, which is the value of HCW that is recorded on the company's balance sheet. Investors also form their own opinion of HCW Biologics' value that differs from its market value or its book value, called intrinsic value, which is HCW Biologics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because HCW Biologics' market value can be influenced by many factors that don't directly affect HCW Biologics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between HCW Biologics' value and its price as these two are different measures arrived at by different means. Investors typically determine if HCW Biologics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, HCW Biologics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
HCW Probability Of Bankruptcy Driver Correlations
Understanding the fundamental principles of building solid financial models for HCW Biologics is extremely important. It helps to project a fair market value of HCW Stock properly, considering its historical fundamentals such as Probability Of Bankruptcy. Since HCW Biologics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of HCW Biologics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of HCW Biologics' interrelated accounts and indicators.
Click cells to compare fundamentals
The Probability of Bankruptcy SHOULD NOT be confused with the actual chance of a company to file for chapter 7, 11, 12, or 13 bankruptcy protection. Macroaxis simply defines Financial Distress as an operational condition where a company is having difficulty meeting its current financial obligations towards its creditors or delivering on the expectations of its investors. Macroaxis derives these conditions daily from both public financial statements as well as analysis of stock prices reacting to market conditions or economic downturns, including short-term and long-term historical volatility. Other factors taken into account include analysis of liquidity, revenue patterns, R&D expenses, and commitments, as well as public headlines and social sentiment.
| Competition |
Based on the latest financial disclosure, HCW Biologics has a Probability Of Bankruptcy of 76%. This is 75.56% higher than that of the Biotechnology sector and 38.58% higher than that of the Health Care industry. The probability of bankruptcy for all United States stocks is 90.81% lower than that of the firm.
HCW Probability Of Bankruptcy Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses HCW Biologics' direct or indirect competition against its Probability Of Bankruptcy to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of HCW Biologics could also be used in its relative valuation, which is a method of valuing HCW Biologics by comparing valuation metrics of similar companies.HCW Biologics is currently under evaluation in probability of bankruptcy category among its peers.
HCW Fundamentals
| Return On Equity | -3.44 | ||||
| Return On Asset | -0.7 | ||||
| Operating Margin | (22.36) % | ||||
| Current Valuation | 44.13 M | ||||
| Shares Outstanding | 37.82 M | ||||
| Shares Owned By Insiders | 52.30 % | ||||
| Shares Owned By Institutions | 3.10 % | ||||
| Number Of Shares Shorted | 8.09 K | ||||
| Price To Book | 2.80 X | ||||
| Price To Sales | 8.24 X | ||||
| Revenue | 2.84 M | ||||
| Gross Profit | 4.1 M | ||||
| EBITDA | (23.58 M) | ||||
| Net Income | (24.99 M) | ||||
| Cash And Equivalents | 32.41 M | ||||
| Cash Per Share | 0.90 X | ||||
| Total Debt | 6.3 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 30.25 X | ||||
| Book Value Per Share | (0.17) X | ||||
| Cash Flow From Operations | (22.51 M) | ||||
| Short Ratio | 0.28 X | ||||
| Earnings Per Share | (1.05) X | ||||
| Target Price | 3.0 | ||||
| Number Of Employees | 45 | ||||
| Beta | 0.84 | ||||
| Market Capitalization | 11.95 M | ||||
| Total Asset | 28.51 M | ||||
| Retained Earnings | (70.53 M) | ||||
| Working Capital | (2.34 M) | ||||
| Net Asset | 28.51 M |
About HCW Biologics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze HCW Biologics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of HCW Biologics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of HCW Biologics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether HCW Biologics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of HCW Biologics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Hcw Biologics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Hcw Biologics Stock:Check out HCW Biologics Piotroski F Score and HCW Biologics Altman Z Score analysis. For information on how to trade HCW Stock refer to our How to Trade HCW Stock guide.You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of HCW Biologics. If investors know HCW will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about HCW Biologics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.05) | Revenue Per Share 0.107 | Quarterly Revenue Growth (0.01) | Return On Assets (0.70) | Return On Equity (3.44) |
The market value of HCW Biologics is measured differently than its book value, which is the value of HCW that is recorded on the company's balance sheet. Investors also form their own opinion of HCW Biologics' value that differs from its market value or its book value, called intrinsic value, which is HCW Biologics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because HCW Biologics' market value can be influenced by many factors that don't directly affect HCW Biologics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between HCW Biologics' value and its price as these two are different measures arrived at by different means. Investors typically determine if HCW Biologics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, HCW Biologics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.